Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.
About
Anagram Therapeutics is a clinical-stage private biopharmaceutical company focused on improving the lives of individuals suffering from exocrine pancreatic insufficiency (EPI) caused by conditions such as cystic fibrosis, pancreatic cancer, and other related disorders. The company is developing ANG003, an orally delivered recombinant enzyme therapy.
Tags
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Anagram Therapeutics do?
Anagram Therapeutics is a clinical-stage private biopharmaceutical company focused on improving the lives of individuals suffering from exocrine pancreatic insufficiency (EPI) caused by conditions such as cystic fibrosis, pancreatic cancer, and other related disorders. The company is developing ANG003, an orally delivered recombinant enzyme therapy.
How much funding has Anagram Therapeutics raised?
Anagram Therapeutics has raised a total of $285M in funding. The most recent round on record is Investment.
Where is Anagram Therapeutics headquartered?
Anagram Therapeutics is headquartered in Natick, Massachusetts, USA.
When was Anagram Therapeutics founded?
Anagram Therapeutics was founded in 2017.
What industry does Anagram Therapeutics operate in?
Anagram Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare, Biotech, Drug Discovery, Clinical Trials.
Similar Startups